Farmas USA

¿Te lo han arreglado ya?

GALE

Neuvax segundo semestre 2016
GALE-301: algún tipo de datos en el primer trimestre de 2016. We are continuing to collect safety, immunologic and clinical recurrence data and expect to present and update in the first half of 2016
VADIS: Phase 2 trial of the Nelipepimut-S Peptide VAccine in Women with DCIS of the Breast.
The trial is expected to initiate in the fourth quarter of 2015

Hola chicos. Siento la noticia a todos los que lleváis THLD (por pelos, hace escasamente un mes, no entro yo), pero es lo que, en el peor de los casos, nos pueden dar las farmas..Paciencia, quien sabe, igual los próximos meses se puede como mínimo, paliar pérdidas.

BLUE . Cae un 30% en PM.. puede esto darnos una señal de entrada ahora en MSTX? Esta micro-cap también anda liada con el SCD (Sickle Cell) y si no voy equivocado, presenta datos relativos al SCD en 1Q/2Q 2016.

Saludos a todos.

athx
si rompe resistencia se subirán y puede tener un rally
resistencias
1.11
1.3x

Si. Menos mal llame a las 8,30 y en 20 minutos estaba arreglado. Mil disculpas y bla bla bla.... Pero los nervios de todo el fin de semans no me quita nadie. El cambio de brokrr esta decidido.

Bueno, órden de venta cambiada a 1$. Espero que entre en la apertura,y a pasar página. Suerte a todo el que esté dentro.

THLD

BLUE

Resumen del Bastardo. Sigo en ello, pero creo que sí puede ser buena entrada.

Bastardo http://www.thestreet.com/story/13387927/1/investors-remain-skeptical-about-bluebird-gene-therapy-for-blood-disease.html
The company emphasized that while patients treated with its gene therapy are not responding quickly, improvements in functional and healthy red blood cells are being seen
incomplete ablation of the patient's bone marrow, prior to the gene therapy infusion, which could explain the slower-than-expected response, Bluebird said.
Investors are more likely to significantly discount or eliminate entirely the sickle cell disease market from Bluebird's valuation until more clarity is provided.
Bluebird is having more success using its gene therapy to treat, perhaps even cure, beta-thalassemia patients, but here, too, investors are worried. Bluebird's gene therapy is less effective for patients with the "beta zero/beta zero" subtype of beta-thalassemia.
These patients have the most severe genetic mutation and are not reaching transfusion independence yet despite treatment with Bluebird's gene therapy. patients, are still benefiting because of less frequent blood transfusions.
Over time, the benefit seen in "beta zero/beta zero" patients could grow, Bluebird believes.
The concern is that simply reducing blood transfusion frequency, but not eliminating it, might not be enough of a benefit to warrant the risk and complexity of undergoing gene therapy.
The company talked at great length Sunday night about its early-stage cancer therapy platform. An engineered T cell therapy targeting a protein known as BCMA found on the surface of multiple myeloma cells will enter clinical trials next year. Bluebird is partnering with Celgene (CELG - Get Report) -- multiple myeloma experts --on this project.
Data from a older version of this BCMA-targeted engineered T cell therapy were presented at ASH this weekend -- and were quite positive.

Thld

Ahi va mi cantaro de leche reventando!

Pues nada chicos,como bien dijeron,cabeza fria y mirar temas de perdidas y plusvalias.

Yo de entrada no tengo prisa,fue un año tranquilo en bolsa, me sobran compañias para vender con perdidas :P

Animo